Tamoxifen EBEWE 20 mg tabletės

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG, Puma Biotechnology Inc.

Conditions

Estrogen Receptor-PositiveHER2-Negative Early Breast CancerHormone receptor positive (HR+)human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

Phase 2

A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer

RecruitingCTIS2024-511497-79-00

Puma Biotechnology Inc.Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

Start: 2024-12-30Target: 54Updated: 2025-12-23

Phase 3

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer

Active, not recruitingCTIS2023-507172-44-00

F. Hoffmann-La Roche AGEstrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Start: 2021-09-10Target: 1482Updated: 2025-11-25